AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.

AFT Orphan Pharmaceuticals judgment
Read More
AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the recruitment and appointment of a replacement independent director to the Board. Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service […]
Read More
Annual Meeting Overview
Read More
June 30th 2023 Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand, on Friday, 4 August 2023 commencing at 10.30am (New Zealand time). Agenda A) Addresses Our Chairman, David Flacks, and […]
Read More
Financial Results for the 12 Months to 31st of March 2023
Read More
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023.
Read More
AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive Maxigesic® IV licensing agreement for eight new European markets.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser
Read More
Diversified pharmaceutical company appoints new north American-based director and launches Maxigesic® in Canada.
Read More
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio
Read More
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces continued growth in revenue and normalised earnings as it benefits from growth across its portfolio.
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) announces the establishment of a new subsidiary in Ireland
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has received a US Food and Drug Administration (FDA) complete response letter (CRL).
Read More
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has today appointed Anita Baldauf as a non-executive director.
Read More
Agreement covers pharmaceutical-grade medicinal cannabis ingredients for products initially targeted for Australia and New Zealand
Read More
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed exclusive Maxigesic IV® distribution and supply agreements for the UK and Hong Kong, with the company targeting sales of the medicine in these territories in 2022.
Read More